Stockreport

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) [...

SCYNEXIS, Inc.  (SCYX) 
Last scynexis, inc. earnings: 11/12 08:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.scynexis.com/investor-relations
PDF A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027 [Read more]